HYAL1 overexpression is correlated with the malignant behavior of human breast cancer

International Journal of Cancer

Volumn 128, Issue 6, 2011, Pages 1303-1315

  Tan, Jin Xiang ^a   Wang, Xiao Yi ^a   Li, Hong Yuan ^a   Su, Xin Liang ^a   Wang, Liang ^b   Ran, Liang ^a   Zheng, Ke ^a   Ren, Guo Sheng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Jiulongpo District   (China)

Author keywords

breast cancer; HYAL1; hyaluronidase; malignant behavior; RNA interference

Indexed keywords

HYALURONIC ACID; HYALURONIDASE; HYALURONIDASE 1; HYALURONIDASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551495576     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25460     Document Type: Article

References (57)

1. Laurent TC, Fraser JR,. Hyaluronan. FASEB J 1992; 6: 2397-404.
2. Delpech B, Girard N, Bertrand P, Courel MN, Chauzy C, Delpech A,. Hyaluronan: fundamental principles and applications in cancer. J Intern Med 1997; 242: 41-8.
3. Tammi MI, Day AJ, Turley EA,. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277: 4581-4.
4. Turley EA, Noble PW, Bourguignon LY,. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277: 4589-92.
5. Toole BP, Wight TN, Tammi MI,. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002; 277: 4593-6.
6. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Agren U, Alhava E, Kosma VM,. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342-7.
7. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM,. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36.
8. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, Böhm J, Hollmén S, Kosma VM,. Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001; 95: 12-7.
9. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M, Lokeshwar BL,. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001; 276: 11922-32.
10. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, Soloway MS, Block NL,. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163: 348-56.
11. Slevin M, Krupinski J, Kumar S, Gaffney J,. Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest 1998; 78: 987-1003.
12. Rooney P, Kumar S, Ponting J, Wang M,. The role of hyaluronan in tumour neovascularization. Int J Cancer 1995; 60: 632-6.
13. Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G, Plum SM, Zhang L, Green SJ,. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 2001; 61: 1022-8.
14. Hayen W, Goebeler M, Kumar S, Riessen R, Nehls V,. Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. J Cell Sci 1999; 112: 2241-51.
15. Udabage L, Brownlee GR, Stern R, Brown TJ,. Inhibition of hyaluronan degradation by dextran sulphate facilitates characterisation of hyaluronan synthesis: an in vitro and in vivo study. Glycoconj J 2004; 20: 461-71.
16. Kreil G,. Hyaluronidases-a group of neglected enzymes. Protein Sci 1995; 4: 1666-9.
17. Tu AT, Hendon RR,. Characterization of lizard venom hyaluronidase and evidence for its action as a spreading factor. Comp Biochem Physiol B 1983; 76: 377-83.
18. Tanabe KK, Nishi T, Saya H,. Novel variants of CD44 arising from alternative splicing: changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Mol Carcinog 1993; 7: 212-20.
19. Lin G, Stern R,. Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Lett 2001; 163: 95-101.
20. Csoka AB, Frost GI, Stern R,. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 20: 499-508.
21. Frost GI, Csóka AB, Wong T, Stern R,. Purification, cloning, and expression of human plasma hyaluronidase. Biochem Biophys Res Commun 1997; 236: 10-5. (Pubitemid 27341829)
22. Csóka AB, Frost GI, Wong T, Stern R,. Purification and microsequencing of hyaluronidase isozymes from human urine. FEBS Lett 1997; 417: 307-10.
23. Lokeshwar VB, Young MJ, Goudarzi G, Iida N, Yudin AI, Cherr GN, Selzer MG,. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res 1999; 59: 4464-70.
24. Triggs-Raine B, Salo TJ, Zhang H, Wicklow BA, Natowicz MR,. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci U S A 1999; 96: 6296-300.
25. Lepperdinger G, Müllegger J, Kreil G,. Hyal2-less active, but more versatile? Matrix Biol 2001; 20: 509-14.
26. Cherr GN, Yudin AI, Overstreet JW,. The dual functions of GPI-anchored PH-20: hyaluronidase and intracellular signaling. Matrix Biol 2001; 20: 515-25.
27. Vines CA, Li MW, Deng X, Yudin AI, Cherr GN, Overstreet JW,. Identification of a hyaluronic acid (HA) binding domain in the PH-20 protein that may function in cell signaling. Mol Reprod Dev 2001; 60: 542-52.
28. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman MI, Miller AD,. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci U S A 2001; 98: 4443-8.
29. West DC, Kumar S,. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 1989; 183: 179-96.
30. Lokeshwar VB, Selzer MG,. Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem 2000; 275: 27641-9.
31. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB,. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 2003; 63: 2638-44.
32. Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB,. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004; 112: 121-9.
33. Wang F, Grigorieva EV, Li J, Senchenko VN, Pavlova TV, Anedchenko EA, Kudryavtseva AV, Tsimanis A, Angeloni D, Lerman MI, Kashuba VI, Klein G, et al. HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro. PLoS One 2008; 3: e3031.
34. Victor R, Chauzy C, Girard N, Gioanni J, d'Anjou J, Stora De Novion H, Delpech B,. Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int J Cancer 1999; 82: 77-83.
35. Bertrand P, Girard N, Duval C, d'Anjou J, Chauzy C, Ménard JF, Delpech B,. Increased hyaluronidase levels in breast tumor metastases. Int J Cancer 1997; 73: 327-31.
36. Wang XY, Tan JX, Vasse M, Delpech B, Ren GS,. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro. Chin Med J 2009; 122: 1300-4.
37. Tan JX, Ren GS, Tu G, Li XT, Wang XY, Ran L,. Effect of silencing of hyaluronidase gene HYAL1 by RNA interference on proliferation of human breast cancer cells. Ai Zheng 2006; 25: 844-8.
38. Udabage L, Brownlee GR, Nilsson SK, Brown TJ,. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005; 310: 205-17.
39. Jeon GA, Lee JS, Patel V, Gutkind JS, Thorgeirsson SS, Kim EC, Chu IS, Amornphimoltham P, Park MH,. Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer 2004; 112: 249-58.
40. Yuan B, Latek R, Hossbach M, Tuschl T, Lewitter F,. siRNA selection server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 2004; 32: 130-4.
41. Tuschl T,. Expanding small RNA interference. Nature Biotech 2002; 20: 446-8.
42. Lokeshwar VB, Schroeder GL, Carey RI, Soloway MS, Iida N,. Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem 2002; 277: 33654-63.
43. Toole BP,. Hyaluronan promotes the malignant phenotype. Glycobiology 2002; 12: 37-42.
44. Rooney P, Wang M, Kumar P, Kumar S,. Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J Cell Sci 1993; 105: 213-8.
45. Sattar A, Rooney P, Kumar S, Pye D, West DC, Scott I, Ledger P,. Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin. J Invest Dermatol 1994; 103: 576-9.
46. Poola I, Abraham J, Marshalleck JJ, Yue Q, Lokeshwar VB, Bonney G, Dewitty RL,. Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clin Cancer Res 2008; 14: 1274-80.
47. Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J, Box G, Eccles S, et al. Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer 2002; 97: 416-24.
48. West DC, Hampson IN, Arnold F, Kumar S,. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985; 228: 1324-6.
49. Slevin M, Kumar S, Gaffney J,. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 277: 41046-59.
50. Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T, Markowitz S, Willson J, Sy MS,. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1996; 93: 7832-7.
51. Lokeshwar VB, Obek C, Soloway MS, Block NL,. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997; 57: 773-7. Erratum in: Cancer Res 1998; 58: 3191.
52. Jacobson A, Rahmanian M, Rubin K, Heldin P,. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002; 102: 212-9.
53. Lokeshwar VB, Cerwinka WH, Lokeshwar BL,. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 2005; 65: 2243-50.
54. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB,. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 2003; 106: 438-45.
55. Simpson MA, Wilson CM, McCarthy JB,. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002; 161: 849-57.
56. Li Y, Li L, Brown TJ, Heldin P,. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 2007; 120: 2557-67.
57. Enegd B, King JA, Stylli S, Paradiso L, Kaye AH, Novak U,. Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery 2002; 50: 1311-8.